HJLI specializes in developing and manufacturing bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two product candidates: the porcine tissue based VenoValveÂŽ, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venue Insufficiency and the CoreoGraftÂŽ, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery. Source
No articles found.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Tyme Inc. is an emerging biotechnology company developing cancer therapeutics that...
Tyme Inc. is an emerging biotechnology company ...
TCR² is an innovative immunotherapy company developing the next generation of T c...
TCR² is an innovative immunotherapy company de...
ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medica...
ICU Medical, Inc. (Nasdaq:ICUI) develops, manuf...
Precipio has built a platform designed to eradicate the problem of misdiagnosis by...
Precipio has built a platform designed to eradi...
We are a gene therapy company dedicated to developing and commercializing novel tr...
We are a gene therapy company dedicated to deve...
The Medicines Company is a biopharmaceutical company driven by an overriding purpo...
The Medicines Company is a biopharmaceutical co...
Join the National Investor Network and get the latest information with your interests in mind.